Use of the KAL protein and treatment with the KAL protein in tre

Details Use of the KAL protein and treatment with the KAL protein in tre Use of the KAL protein and treatment with the KAL protein in tre

1996-12-06

2000-09-19

Duffy, Patricia A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 8, 514 12, 530300, 530350, A01N 3718, A61K 3800

Patent

active

061212318

ABSTRACT:
KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

REFERENCES:
Jackowski et al, British Journal of Neurosurgery, 9:303-317, 1995.
Barinaga, M., Science, 264:772-774, 1994.
Del Castillo et al, Methods in Molecular and Cellular Biology, 4:87-92, 1993.
Legouis et al, Cell, 67:423-435, 1991.
Rapp, L.M. in Handbook of Neurotoxicology, Chang et al eds., Marcel Dekker Inc, 1995 pp. 963-1003.
Sambrook et al., Molecular Cloning A Laboratory Manulal, Second Edition, vol. 3, pp 16.1-16.80, Cold Spring Harbor Press, 1989.
Buttiglione et al., "F3 Neuronal Adhesion Molecule Controls Outgrowth and Fasciculation of Cerebellar Granule Cell Neurites: A Cell-Type-Specific Effect Mediated by the Ig-Like Domains", Molecular and Cellular Neuroscience 000, pp. 1-17, (1996).
Chang et al., "Extension of Neurites on Axons is Impaired by Antibodies Against Specific Neural Cell Surface Glycoproteins", The Journal of Cell Biology, vol. 104, pp. 355-362, Feb. 1987.
Castillo et al., "Structure of the X-Linked Kallmann Syndrome Gene and Its Homologous Pseudogene on the Y Chromosome", Nature Genetics, vol. 2, pp. 305-310, Dec. 1992.
Kunz et al., "Intracellular Signaling is Changed After Clustering of the Neural Cell Adhesion Molecules Axonin-1 and NgCAM During Neurite Fasciculation", The Journal of Cell Biology, vol. 135, No. 1, pp. 253-266, oct. 1996.
Soussi-Yanicostas et al., "Initial Characterization of Anosmin-1, a Putative Extracellular Matrix Protein Synthesized by Definite Neuronal Cell Populations in the Central Nervous System", Journal of Cell Science 109, 1749-1757, (1996).

Affiliated with

Also associated with

Rating

Use of the KAL protein and treatment with the KAL protein in tre does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of the KAL protein and treatment with the KAL protein in tre, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the KAL protein and treatment with the KAL protein in tre will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1073253